Nasdaq
$1.90▲ 74.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.1MShares out 0.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
23- 1d agoPre-market26.10.23 20:006-KKey event#●●●#●●●#●●●
SciSparc Ltd.Bullish
SciSparc's subsidiary, NeuroThera Labs, has successfully completed the manufacturing and European Qualified Person (QP) batch release certification for its investigational product, SCI-110. This milestone enables the activation of clinical sites and the initiation of patient enrollment for the FDA-approved Phase IIb clinical trial for Tourette Syndrome.…more
$1.90+74.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Regular26.10.16 02:306-KKey event
SciSparc Ltd.
On October 15, 2026, SciSparc entered into an agreement with L.I.A Pure Capital to convert a convertible promissory note totaling $2,023,039.21 in principal and interest into ordinary shares at a price of $1.50 per share. The transaction involves no additional cash payment, and the resulting shares are freely tradable under an effective registration statement.…more
$1.90+74.31%vs prev closeView filingShare - 10.15Regular26.10.16 00:476-KKey event
SciSparc Ltd.
SciSparc has officially announced a strategic shift from its existing pharmaceutical business to the Agentic AI sector, including cybersecurity and finance technologies. The company intends to evaluate technologies and business opportunities within this ecosystem moving forward.…more
$1.90+74.31%vs prev closeView filingShare
22 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoPre-market26.10.22 21:55#●●●#●●●
SciSparc Subsidiary Advances Phase IIb Clinical Trial for Tourette Syndrome…more
SciSparc's subsidiary, NeuroThera Labs, has completed the manufacturing and certification of its investigational drug SCI-110 for a Phase IIb clinical trial. This milestone enables the company to proceed with patient enrollment and site activation for the Tourette Syndrome study.…more
$1.90+74.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 4d agoPre-market26.10.19 21:35
●●●●●●●● ●●●●● ●●●●●●
SciSparc announced a strategic shift toward Agentic AI technologies, specifically targeting the cybersecurity and finance sectors. The company is currently evaluating potential opportunities, though no commercial agreements or revenue-generating activities have been confirmed.…more
$1.90+74.31%vs prev close - 10.15Regular26.10.16 03:47
●●●●●●●● ●●●●● ●●●●●●
SciSparc has agreed to convert $2.02 million in outstanding convertible notes into ordinary shares at a price of $1.50 per share. This transaction involves debt-to-equity conversion, resulting in no new cash proceeds and potential share dilution.…more
$1.90+74.31%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report